Skip to main content

Table 1 Combination index analysis

From: Alternative dosing of dual PI3K and MEK inhibition in cancer therapy

Cell line PI3K inhibitor CI (ED50) Average CI Range Significance
H1437 ZSTK474 0,4 0,3 0,1-0,3 Strong synergism
H1437 PI-103 0,2    
H3122 ZSTK474 0,27 0,325 0,3-0,7 Synergism
H3122 PI-103 0,38    
MDA-MB231 ZSTK474 0,58 0,515 0,3-0,7 Synergism
MDA-MB231 PI-103 0,45    
HCT116 ZSTK474 0,4 0,635 0,3-0,7 Synergism
HCT116 PI-103 0,87    
DFCI032 ZSTK474 0,61 0,71 0,7-0,85 Moderate synergism
DFCI032 PI-103 0,81    
H358 ZSTK474 0,6 0,79 0,7-0,85 Moderate synergism
H358 PI-103 0,98    
H2228 ZSTK474 0,87 0,885 0,85-0,9 Slight synergism
H2228 PI-103 0,9    
A549 ZSTK474 0,9 0,93 0,90-1,10 Nearly additive
A549 PI-103 0,96    
H441 ZSTK474 1,14 1,07 0,90-1,10 Nearly additive
H441 PI-103 1    
A431 ZSTK474 1,17 1,19 1,10-1,20 Slight antagonism
A431 PI-103 1,21    
HCC827 ZSTK474 0,89 1,45 1,20-1,45 Moderate antagonism
HCC827 PI-103 2,01    
PC9 ZSTK474 1,37 1,65 1,20-1,45 Antagonism
PC9 PI-103 1,93    
H1518 ZSTK474 1,2 1,72 1,45-3,3 Antagonism
H1518 PI-103 2,24    
H1975 ZSTK474 2,3 1,745 1,45-3,3 Antagonism
H1975 PI-103 1,19